Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enecadin SCHEMBL678822 | 1.00 | HRH3 (0.55) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL29406882 | 0.99 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL562985 | 0.99 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL5420925 | 0.99 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL6587974 | 0.99 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL5420920 | 0.99 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| SCHEMBL4603419 | 0.99 | HRH3 (0.53) | HRH3MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL6593396 | 0.98 | HRH3 (0.52) | HRH3MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL6586710 | 0.94 | KCNH2 (0.53) | HRH3KCNH2ACP1 | |
| Hydrochloric Acid SCHEMBL6587345 | 0.91 | KCNH2 (0.47) | KCNH2ACP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1941879-A1 | Neuroprotective agent for the treatment of neuronal damage | PAION Deutschland GmbH (DE) | 2008-07-09 | — | — | EP | claimed |
| US-20070021451-A1 | Method for preventing or treating neurologic damage after spinal cord injury | HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2007-01-25 | — | — | US | claimed |
| EP-0781766-B1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2004-03-31 | — | — | EP | claimed |
| US-5945426-A | PREVENT NEURONAL DEATH | NIPPON SHINYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | claimed |
| EP-0781766-A1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | claimed |
| EP-1941879-A1 | Neuroprotective agent for the treatment of neuronal damage | PAION Deutschland GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070021451-A1 | Method for preventing or treating neurologic damage after spinal cord injury | HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2007-01-25 | — | — | US | disclosed |
| EP-0781766-B1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6191149-B1 | DRUG FOR CEREBROVASCULAR DISEASE | NIPPON SHINYAKU, CO., LTD. (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5945426-A | PREVENT NEURONAL DEATH | NIPPON SHINYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0781766-A1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021451-A1 | Method for preventing or treating neurologic damage after spinal cord injury | SMN1; SMN2, AQP4, GAP43 | HRH3 3019/4885MEN1 4187/4885KMT2A 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.